# Pharma Collaboration Handoff

## Current checkpoint

- Module: `Pharma`
- Phase: Major Refactor — Final Acceptance + Closeout
- Branch: `docs/pharma-major-refactor-final-acceptance-closeout`
- Base checkpoint: `main@c5d6e4b341c5f99f2bf73d8104fba0975ddd5375`
- Status: **MR-7 FINAL ACCEPTANCE PASSED — READY FOR PR REVIEW**
- Date: 2026-08-30
- Application source modified in MR-7: **NO**
- Documentation modified in MR-7: **YES**
- Production/runtime enablement changed: **NO**

## Major Refactor delivery status

The planned Pharma Major Refactor implementation is complete through MR-6 and has passed the MR-7 final acceptance gate.

Merged delivery record:

- PR #88 — MR-1 Security Foundation + MR-2 Shared Import/Export Hardening.
- PR #89 — dedicated Pharma Admin Dashboard at `/admin/pharma`.
- PR #90 — MR-3 Medicine/HSSP Workspace.
- PR #91 — MR-4 Drug Bid Award Workspace + Sync-Ready Foundation.
- PR #92 — MR-5 Supplier Tracking Integrity + Workspace.
- PR #93 — MR-6 Price List Security + Pipeline, merged as `c5d6e4b341c5f99f2bf73d8104fba0975ddd5375`.

MR-7 intentionally introduces no new application feature. It validates the merged result and closes the refactor documentation.

## Final accepted architecture

### Security boundary

- Pharma Admin routes are behind `web` + `auth:admin`.
- Dashboard/index/create/edit routes enforce the appropriate Pharma capabilities.
- Sensitive Livewire mutations use server-side capability checks.
- Pharma exposes no public API contract; `routes/api.php` is intentionally empty of routes.

### Admin workspaces

- Dashboard provides the canonical Pharma entry point.
- Medicine/HSSP, Drug Bid Award, Supplier Tracking and PriceList use the Admin shell and Dashboard return navigation.
- Production-facing list workspaces use bounded `10/25/50/100` pagination rather than `All`.
- Bulk selection is page-scoped and destructive operations use explicit confirmation/permission boundaries.
- Large Medicine selectors were replaced with bounded lookup behavior where refactored.

### Import/export and generated files

- Pharma reuses the Shared Import/Export infrastructure.
- Shared service resolution is hardened against mutable client-side service substitution.
- Generated Shared exports are private and use authorized download behavior.
- PriceList generation uses a private service-controlled output directory and does not trust a request-controlled output path.

### Domain integrity

- Drug Bid Awards include stable source metadata and idempotent source projection for future synchronization.
- Supplier Tracking enforces the accepted normalized supplier business key when working date is non-null.
- Medicine -> Supplier Tracking cascade-delete behavior remains intentionally unchanged.
- PriceList workbook analysis remains server-side rather than public Livewire state.

## MR-7 final acceptance evidence

Executed on the dedicated closeout branch based on merged `main@c5d6e4b341c5f99f2bf73d8104fba0975ddd5375`.

### Route inventory

```bash
php artisan route:list --path=admin/pharma
```

Result: **PASS — 11 Pharma Admin routes**.

Accepted route surface:

- Pharma Dashboard;
- Medicine/HSSP index/create/edit;
- Drug Bid Award index/create/edit;
- Supplier Tracking index/create/edit;
- Price List create.

### Focused Pharma regression

```bash
php artisan test tests/Feature/Pharma Modules/Pharma/Tests
```

Result: **PASS — 41 tests, 240 assertions** in 2.93s.

No full-project suite was run; verification remains intentionally scoped to Pharma and directly impacted behavior.

### Frontend production build

```bash
npm run build
```

Result: **PASS — Vite production build, 34 modules transformed** in 1.90s.

### UI acceptance lineage

MR-6 PriceList final manual UI smoke was **PASS** immediately before PR #93 merge. Earlier Medicine, Drug Bid Award, Supplier Tracking and Dashboard delivery phases were likewise manually accepted before their respective merges.

No new application UI was introduced by MR-7, so no additional MR-7 UI change requires acceptance.

## Documentation closeout

`docs/modules/Pharma/ANALYSIS.md` has been refreshed from the pre-refactor risk inventory to the accepted post-refactor architecture. Findings already resolved by MR-1 through MR-6 are no longer presented as current defects.

The final analysis now records:

- accepted security and authorization boundaries;
- Shared Import/Export hardening;
- bounded Admin workspaces;
- Drug Bid Award sync-ready source identity;
- Supplier Tracking business-key integrity;
- PriceList server-only/private pipeline;
- final route/test/build evidence;
- explicit future/deferred scope.

## Intentional deferred scope / non-goals

The following remain outside the completed Major Refactor and are **not blockers** for closeout:

- actual Muasamcong -> Pharma production synchronization/wiring;
- automated fuzzy Medicine matching;
- production/runtime enablement of Pharma;
- PriceList database entity/table;
- PriceList queue/background generation unless future benchmarking proves it necessary;
- user upload/replacement of the PriceList source workbook;
- switching PriceList source data to Medicine database records;
- changing Medicine -> Supplier Tracking cascade-delete policy;
- unrelated project-wide refactoring/regression.

The tracked Pharma manifest remains `enabled => false`.

## Closeout decision

**Recommendation: merge MR-7 and close the Pharma Major Refactor program.**

After MR-7 is merged, there is no automatically authorized next implementation MR. Any future Pharma work must start from a concrete user objective and a new analysis/plan before code changes.

Likely future initiatives, only if explicitly requested, include:

- Muasamcong -> Pharma synchronization;
- Pharma production enablement/readiness;
- PriceList source/queue evolution;
- new Pharma business features.

Do not begin any of these from this handoff without explicit user approval.
